PBMares Wealth Management LLC Has $1.38 Million Position in Johnson & Johnson (NYSE:JNJ)

PBMares Wealth Management LLC trimmed its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 5.1% in the first quarter, according to its most recent filing with the SEC. The firm owned 8,334 shares of the company’s stock after selling 452 shares during the period. PBMares Wealth Management LLC’s holdings in Johnson & Johnson were worth $1,382,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. WealthTrak Capital Management LLC acquired a new stake in Johnson & Johnson during the fourth quarter valued at approximately $26,000. Mountain Hill Investment Partners Corp. bought a new position in shares of Johnson & Johnson during the 4th quarter worth approximately $29,000. Conquis Financial LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $33,000. Bernard Wealth Management Corp. bought a new stake in Johnson & Johnson in the fourth quarter valued at $36,000. Finally, Runnymede Capital Advisors Inc. acquired a new position in Johnson & Johnson during the fourth quarter worth $38,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 0.1%

Shares of JNJ opened at $152.33 on Thursday. The stock’s fifty day simple moving average is $153.95 and its 200-day simple moving average is $153.67. The company has a quick ratio of 1.03, a current ratio of 1.26 and a debt-to-equity ratio of 0.49. The firm has a market capitalization of $366.52 billion, a PE ratio of 16.94, a price-to-earnings-growth ratio of 2.31 and a beta of 0.42. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. Johnson & Johnson had a net margin of 24.42% and a return on equity of 33.46%. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Tuesday, May 27th were given a $1.30 dividend. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.24. This represents a $5.20 annualized dividend and a dividend yield of 3.41%. The ex-dividend date of this dividend was Tuesday, May 27th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analyst Weigh In

Several equities research analysts have recently weighed in on JNJ shares. The Goldman Sachs Group raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and upped their target price for the stock from $157.00 to $172.00 in a report on Wednesday, April 9th. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Johnson & Johnson in a research note on Wednesday, April 16th. Leerink Partners lowered shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and dropped their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Raymond James Financial reduced their target price on Johnson & Johnson from $165.00 to $162.00 and set an “outperform” rating on the stock in a report on Monday, April 14th. Finally, Benchmark raised Johnson & Johnson to a “strong-buy” rating in a report on Thursday, April 24th. Eleven research analysts have rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson presently has an average rating of “Moderate Buy” and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.